![]() |
|
|
Vol. 57, Issue 6, 1132-1141, June 2000
Janssen Research Foundation, Department of Biochemical
Pharmacology, Beerse, Belgium (R.B., K.J., M.J., P.L., W.G., J.E.L.),
University of Cagliari, Department of Neuroscience, Cagliari, Italy
(M.P.C.)
The 5-hydroxytryptamine (5-HT) 1D/1B receptors have gained particular
interest as potential targets for treatment of migraine and depression.
G-protein coupling and other intrinsic properties of the human
5-HT1D receptor were studied using a baculovirus-based expression system in Sf9 cells. Coexpression of the human
5-HT1D receptor with G
i1,
i2,
i3, or G
o-proteins and
G
1
2-subunits reconstituted a
Gpp(NH)p-sensitive, high affinity binding of [3H]5-HT to
this receptor, whereas the
G
q
1
2 heterotrimer was ineffective in this respect. Competition of [3H]5-HT
binding by various compounds confirmed that coexpression of the human
5-HT1D receptor with
G
i/o
1
2 reconstitutes the receptor in a high affinity agonist binding state, having the same
pharmacological profile as the receptor expressed in mammalian cells.
Binding of the antagonist ocaperidone to the human 5-HT1D receptor in coupled or noncoupled state was analyzed. This compound competed with [3H]5-HT binding more potently on the human
5-HT1D receptor in the noncoupled state, showing its
inverse agonistic character. Ocaperidone acted as a competitive
inhibitor of [3H]5-HT binding when tested with the
coupled receptor form but not so when tested with the noncoupled
receptor preparation. Finally, [35S]GTP
S binding
experiments using the inverse agonist ocaperidone revealed a high level
of constitutive activity of the human 5-HT1D receptor.
Taken together, the reconstitution of the human 5-HT1D receptor-G-protein coupling using baculovirus-infected Sf9 cells made
possible the assessment of coupling specificity and the detection of
different binding states of the receptor induced by G-protein coupling
or ligand binding.
This article has been cited by other articles:
![]() |
W. R. Leifert, A. L. Aloia, O. Bucco, R. V. Glatz, and E. J. McMurchie G-Protein-Coupled Receptors in Drug Discovery: Nanosizing Using Cell-Free Technologies and Molecular Biology Approaches J Biomol Screen, December 1, 2005; 10(8): 765 - 779. [Abstract] [PDF] |
||||
![]() |
T. Kenakin Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse Agonism Mol. Pharmacol., January 1, 2004; 65(1): 2 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Masuda, H. Itoh, T. Sakihama, C. Akiyama, K. Takahashi, R. Fukuda, T. Yokomizo, T. Shimizu, T. Kodama, and T. Hamakubo A Combinatorial G Protein-coupled Receptor Reconstitution System on Budded Baculovirus: EVIDENCE FOR G{alpha}i AND G{alpha}o COUPLING TO A HUMAN LEUKOTRIENE B4 RECEPTOR J. Biol. Chem., June 27, 2003; 278(27): 24552 - 24562. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Quillan, K. W. Carlson, C. Song, D. Wang, and W. Sadee Differential Effects of {micro}-Opioid Receptor Ligands on Ca2+ Signaling J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1002 - 1012. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wenzel-Seifert, M. T. Kelley, A. Buschauer, and R. Seifert Similar Apparent Constitutive Activity of Human Histamine H2-Receptor Fused to Long and Short Splice Variants of Gsalpha J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1013 - 1020. [Abstract] [Full Text] [PDF] |
||||